New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors
Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[125I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including...
Main Authors: | Olivier Nosjean, Jean A. Boutin, Jean-Louis Brayer, Philippe Delagrange, Daniel-Henri Caignard, Gérald Guillaumet, Pascal Berthelot, François Lefoulon, Emmanuel Thomas, Franck Suzenet, Benoît Folleas, Saïd Yous, Werner Hassler, Teresa Grelak, Sandrine Pedragona-Moreau, Ulrich Matthey, Céline Legros |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/14/5/8948 |
Similar Items
-
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
by: Berthold A. Nock, et al.
Published: (2023-04-01) -
Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01) -
Editorial: Response assessment of radioligand therapies
by: Egesta Lopci, et al.
Published: (2022-07-01) -
Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
by: Joseph Lau, et al.
Published: (2022-08-01) -
PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
by: Alessio Rizzo, et al.
Published: (2022-08-01)